Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) chief medical officer Dr Carman Giacomantonio joined Steve Darling from Proactive to discuss the company's innovative targeted hyperthermia technology for cancer treatment. This cutting-edge approach utilizes gold nanoparticles activated by near-infrared light to heat tumor tissue to a controlled temperature range of 42–48°C, selectively stressing cancer cells while preserving healthy tissue. Dr. Giacomantonio explained that this method has the potential to trigger immune system activation, effectively converting "cold tumors" (which do not naturally provoke immune responses) into "hot tumors" that do. Sona Nanotech has already demonstrated this effect in colon cancer and is now expanding its research into brain cancer. The company's findings were recently published in Frontiers in Immunology, a respected peer-reviewed journal, further validating its approach. Dr. Giacomantonio emphasized that this scientific recognition not only strengthens the credibility of Sona’s technology but also opens doors for potential industry collaborations. Looking ahead, Sona Nanotech is preparing to launch a clinical trial to assess the feasibility and safety of this approach in humans. The ultimate goal is to develop a practical, minimally invasive cancer treatment that eliminates the need for complex surgical procedures. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTreatment #MedicalInnovation #HyperthermiaTherapy #GoldNanoparticles #Immunotherapy #TargetedTherapy #CancerResearch #Biotech #MedicalBreakthrough